Skip to main content
OpenTrials
Completed

NCT Number: NCT05302674

Short- and Long-term Health Consequences of Workers During Consecutive Days of Heat Stress

The purpose of this study is to measure fatigue and indicators of acute kidney injury during consecutive days of work in a hot environment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heat Stress Fatigue Heat Stress Disorders Pathological Conditions, Signs and Symptoms Signs and Symptoms Wounds and Injuries

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Research and Education in Special Environments

Buffalo, New York, 14214, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy individuals
  • Regularly completes aerobic exercise at least 60 min per week

Exclusion criteria

  • History of cardiovascular, metabolic, respiratory, neural, or renal disease
  • Hypertensive or tachycardic during the screening visit (Systolic Blood Pressure > 139 mmHg, Diastolic Blood Pressure > 89 mmHg, heart rate > 100 bpm)
  • Current tobacco or nicotine use or previous regular use within the past 2 years
  • Current or previous musculoskeletal injury limiting physical activity
  • Taking medications with known thermoregulatory or cardiovascular effects (e.g., aspirin, beta blockers, diuretics, psychotropics, etc.)
  • A positive pregnancy test at any point during the study or currently breastfeeding
  • Study physician discretion based on any other medical condition or medication

Treatment and study plan

Hot Dry

Other

98°F (36.7°C) and 20% relative humidity environment

Primary outcomes

  1. Change from baseline in fatigue

    Time frame: Hour 4

    Fatigue will be measured using accelerometry, with the primary variable being jerk, the smoothness or unevenness of movement.

  2. Biomarkers of acute kidney injury

    Time frame: Hour 4

    Tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) are biomarkers that have the potential for early prediction of acute kidney injury.

Sponsors and collaborators

Lead sponsor

State University of New York at Buffalo

Other

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Mar 31, 2022
Registry last updated
Jun 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.